The Impact of Time Restricted Eating on Type 2 Diabetes

Stopped early · Not applicable

Conditions studied: Type 2 Diabetes

In brief

Time-restricted feeding limits caloric intake to active daytime hours with fasting for 14 to 16 hours. It has shown great promise as a novel intervention for stabilizing blood glucose, reducing weight, and improving cardiovascular disease outcomes. However, this approach has not been tested on people with diabetes, a group that would benefit from improved blood glucose and weight loss. The impact of Time-Restricted Eating on Type 2 Diabetes Study (EaT2D Study) is a randomized six-day weight stable crossover feeding study in the Day Patient/Outpatient unit of The Rockefeller Hospital investigating how the time of day that meals are eaten affects weight, blood sugar and blood pressure. The investigators will compare an early time-restricted eating intervention (80% of calories consumed before 2 pm) to a usual feeding pattern (50% of calories consumed after 4 pm) among 10 persons with type 2 diabetes to determine effects on blood sugar and small molecules found in the blood. Studies have shown benefits of eating during active periods (mornings and early afternoon) for metabolic health (blood sugar, body weight) compared to eating during inactive periods (evening and bedtime). Eating earlier in the day may lead to reduced sugar stores, burning fat for energy, and decreased inflammation when compared to eating later in the day. The investigators will compare the effects of eating earlier during the day for six days versus later in the day for six days, on blood sugar, blood pressure, blood ketones, and other measures of metabolic health in diabetic participants. Studies in animals supports these benefits.

Key facts

Study ID

NCT06887543

Run by

Rockefeller University

People needed

2

Starts

2025-05-29

Expected to finish

2025-08-04

Last updated by the study team

2026-01-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-75 able to give consent
• BMI >25 kg/m2
• Hemoglobin A1C ≥ 6.5%
• Willing to eat only the food provided
• Willing to follow the feeding schedule, including fasting for 16 hours/day for six days.
• Usual sleep time is between 10 PM and 8 AM
• Fluent in the English language

You may not qualify if…

• Current use of anti-obesity medications (Ozempic, Mounjaro, Trulicity, Wegovy, Zepbound, Qsymia, Contrave, Saxenda, Victoza, Orlistat)
• Report history of Cirrhosis
• HIV positive
• Self-reported autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, psoriasis, etc.)
• Current use of steroids (inhalers are permissible)
• Currently pregnant
• Smoked tobacco within the last 3 months
• Allergy to adhesive tape
• Skips breakfast
• Followed TRF or intermittent fasting in the last 2 weeks
• Shift or night worker
• Current use of insulin
• Current use of sulfonylureas
• Current use of glucagon-like peptide-1 (GLP-1) receptor agonists
• Hemoglobin A1c >8%
• Unable to sync smartphone with Bluetooth for scale data
• Any medical, psychological, or social condition that, in the opinion of the investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.

Where it is running

• The Rockefeller University Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.